Bluebird bio Inc. (BLUE:NSD) Analysts rate with a Underperform, 6 Negative Signals

STA Research
by: STA Research
Bluebird bio Inc.

Based on the Bluebird bio stock forecast from 8 analysts, the average analyst BLUE stock price target is USD 5.58 over the next 12 months. Bluebird bio Inc’s average analyst rating is Underperform. Stock Target Advisor’s own stock analysis of Bluebird bio stock is Bearish, which is based on 1 positive signal and 6 negative signals. At the last closing, Bluebird bio stock price was USD 6.78Bluebird bio stock price has changed by +0.85% over the past week, +1.97% over the past month and -62.52% over the last year.

Bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel, lovotibeglogene autotemcel, and elivaldogene autotemcel. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty-Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

 

What we like:

Low volatility:  

The annual returns for Bluebird bio stock have been stable and consistent compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

 

What we don’t like:

Poor risk adjusted returns:

Bluebird bio stock is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.

Below median dividend returns:

The average income yield of Bluebird bio stock over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value:

BLUE stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow:

BLUE stock price had negative total cash flow in the most recent four quarters.

Negative free cash flow:

Bluebird bio stock had negative total free cash flow in the most recent four quarters.

Low Revenue Growth:

BLUE stock price has shown below median revenue growth in the previous 5 years compared to its sector

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.